Phio Pharmaceuticals Outlines New PH-762 Program For Common Skin Cancer In US Patients

Benzinga

2022-12-22

Phio Pharmaceuticals Corp (NASDAQ: PHIO) said it expects to file an IND in the U.S. in the first half of 2023 for a Phase 1b clinical trial of its INTASYL compound, PH-762.
Phio is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology is designed to make immune cells more effective in killing tumor cells.
PH-762 has been shown to reduce the expression of PD-1, a protein that inhibits T cells' ability to kill cancer cells. When administered intratumorally in preclinical models, PH-762 primes an anti-tumor immune response and inhibits tumor growth.
Related: Phio Pharma's New Preclinical Data Shows PH-894 Enhances Activity of Cancer CAR-T Cells.
Phio is currently conducting a Phase 1b clinical trial of PH-762 for advanced melanoma.
Phio expects to commence a US Phase 1b clinical trial early in the 2nd half of 2023. The initial US trial is expected to focus on cutaneous squamous cell carcinoma and other selected cutaneous malignancies.
Price Action: PHIO shares are up 4.08% at $0.39 during the premarket session on the last check Thursday.

See more from Benzinga

ORIC Pharmaceuticals Shares Move Higher After Equity Infusion, Clinical Collaboration From Pfizer
Akero Therapeutics Outlines Expected 2023 Milestones For Lead NASH Program
Here's How Much Marjorie Taylor Greene Has Lost On Her Trump SPAC Investment - Digital World Acq (NASDAQ:

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2293582079"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2293582079\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2293582079?lang=zh_CN&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d_hG4z8te1Kd8U0mcLyqXQ--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/0e83811eed1095368a143359b67e9c43","is_english":true,"pubTime":"2022-12-22 21:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2293582079","market":"us","top_or_hot":-1,"title":"Phio Pharmaceuticals Outlines New PH-762 Program For Common Skin Cancer In US Patients","media":"Benzinga","content":"<html><body><img height=\"400\" src=\"https://s.yimg.com/uu/api/res/1.2/oKP4vRHHmDq2aJIeZSr3pg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/Benzinga/0e83811eed1095368a143359b67e9c43\" title=\"\" width=\"600\"/>\n<ul>\n<li><strong>Phio Pharmaceuticals Corp</strong> (NASDAQ: PHIO) said it expects to file an IND in the U.S. in the first half of 2023 for a Phase 1b clinical trial of its INTASYL compound, PH-762. </li>\n<li>Phio is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology is designed to make immune cells more effective in killing tumor cells. </li>\n<li>PH-762 has been shown to reduce the expression of PD-1, a protein that inhibits T cells' ability to kill cancer cells. When administered intratumorally in preclinical models, PH-762 primes an anti-tumor immune response and inhibits tumor growth.</li>\n<li><strong><em>Related:</em></strong><em> </em><em>Phio Pharma's New Preclinical Data Shows PH-894 Enhances Activity of Cancer CAR-T Cells</em><em>.</em></li>\n<li>Phio is currently conducting a Phase 1b clinical trial of PH-762 for advanced melanoma.</li>\n<li>Phio expects to commence a US Phase 1b clinical trial early in the 2nd half of 2023. The initial US trial is expected to focus on cutaneous squamous cell carcinoma and other selected cutaneous malignancies.</li>\n<li><strong>Price Action:</strong> PHIO shares are up 4.08% at $0.39 during the premarket session on the last check Thursday.</li>\n</ul>\n<p><strong>See more from Benzinga</strong></p>\n<ul>\n<li>ORIC Pharmaceuticals Shares Move Higher After Equity Infusion, Clinical Collaboration From Pfizer</li>\n<li><a href=\"https://laohu8.com/S/AKRO\">Akero Therapeutics</a> Outlines Expected 2023 Milestones For Lead NASH Program</li>\n<li>Here's How Much Marjorie Taylor Greene Has Lost On Her Trump SPAC Investment - Digital World Acq (NASDAQ:</li>\n</ul>\n<p>Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.</p>\n<p><i>© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.</i></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Phio Pharmaceuticals Outlines New PH-762 Program For Common Skin Cancer In US Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhio Pharmaceuticals Outlines New PH-762 Program For Common Skin Cancer In US Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-22 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/phio-pharmaceuticals-outlines-ph-762-130008477.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Phio Pharmaceuticals Corp (NASDAQ: PHIO) said it expects to file an IND in the U.S. in the first half of 2023 for a Phase 1b clinical trial of its INTASYL compound, PH-762. \nPhio is a clinical-stage ...</p>\n\n<a href=\"https://finance.yahoo.com/news/phio-pharmaceuticals-outlines-ph-762-130008477.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0070302665.USD","symbol_name":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/phio-pharmaceuticals-outlines-ph-762-130008477.html","article_id":"2293582079","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d_hG4z8te1Kd8U0mcLyqXQ--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/0e83811eed1095368a143359b67e9c43"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2293582079","pubTimestamp":1671714008,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Phio Pharmaceuticals Corp (NASDAQ: PHIO) said it expects to file an IND in the U.S. in the first hal","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","PHIO":"Phio Pharmaceuticals","BK4580":"工业 4.0","NGD":"New Gold","BK4570":"地缘局势概念股","BK4161":"工业机械","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","BK4017":"黄金","PH":"汉尼汾","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","BK4585":"ETF&股票定投概念","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD"},"translate_title":"Phio Pharmaceuticals概述了针对美国患者常见皮肤癌的新PH-762计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NGD":1,"PH":1,"PHIO":0.6,"PHIOW":0.9},"content_text":"Phio Pharmaceuticals Corp (NASDAQ: PHIO) said it expects to file an IND in the U.S. in the first half of 2023 for a Phase 1b clinical trial of its INTASYL compound, PH-762. \nPhio is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology is designed to make immune cells more effective in killing tumor cells. \nPH-762 has been shown to reduce the expression of PD-1, a protein that inhibits T cells' ability to kill cancer cells. When administered intratumorally in preclinical models, PH-762 primes an anti-tumor immune response and inhibits tumor growth.\nRelated: Phio Pharma's New Preclinical Data Shows PH-894 Enhances Activity of Cancer CAR-T Cells.\nPhio is currently conducting a Phase 1b clinical trial of PH-762 for advanced melanoma.\nPhio expects to commence a US Phase 1b clinical trial early in the 2nd half of 2023. The initial US trial is expected to focus on cutaneous squamous cell carcinoma and other selected cutaneous malignancies.\nPrice Action: PHIO shares are up 4.08% at $0.39 during the premarket session on the last check Thursday.\n\nSee more from Benzinga\n\nORIC Pharmaceuticals Shares Move Higher After Equity Infusion, Clinical Collaboration From Pfizer\nAkero Therapeutics Outlines Expected 2023 Milestones For Lead NASH Program\nHere's How Much Marjorie Taylor Greene Has Lost On Her Trump SPAC Investment - Digital World Acq (NASDAQ:\n\nDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.\n© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}